Evidence map›Paper›PMID 28879519›Full record

ArticleInvestigational new drugs2018

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF

Yutaka Fujiwara, Naoya Yamazaki, Yoshio Kiyohara, Shusuke Yoshikawa, Noboru Yamamoto, Arata Tsutsumida, Hiroshi Nokihara, Kenjiro Namikawa, Akihira Mukaiyama, Fanghong Zhang and 1 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. DNA methylation alterations as therapeutic prospects in thyroid cancer.Journal of endocrinological investigation · 2019
    Review
  4. Review
  5. Targeted Therapy and Immunotherapy for Melanoma in Japan.Current treatment options in oncology · 2019
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yutaka FujiwaraDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. yutakafu@ncc.go.jp.
Naoya YamazakiDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yoshio KiyoharaDermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Shusuke YoshikawaDermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Noboru YamamotoDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Arata TsutsumidaDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi NokiharaDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kenjiro NamikawaDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Akihira MukaiyamaDevelopment Department, Novartis Pharma K.K, Tokyo, Japan.
Fanghong ZhangDevelopment Department, Novartis Pharma K.K, Tokyo, Japan.
Tomohide TamuraThoracic Center, St. Luke's International Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Dabrafenib is a BRAF inhibitor that has demonstrated clinical activity with a good tolerability profile in patients with BRAF

Indexed as

Asian PeopleAdultDose-Response Relationship, DrugFemaleHumansImidazolesMaleMiddle AgedMutationNeoplasmsOximesProto-Oncogene Proteins B-rafTreatment OutcomedabrafenibImidazolesOximesProto-Oncogene Proteins B-rafBRAF V600DabrafenibJapaneseMalignant melanomaMutationSolid tumor

Identifiers

PMID28879519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.